These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11893750)

  • 41. TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor.
    Spiesbach K; Tannapfel A; Mössner J; Engeland K
    Int J Cancer; 2005 Apr; 114(4):555-62. PubMed ID: 15578720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The C terminus of p53 family proteins is a cell fate determinant.
    Harms KL; Chen X
    Mol Cell Biol; 2005 Mar; 25(5):2014-30. PubMed ID: 15713654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SSRP1 functions as a co-activator of the transcriptional activator p63.
    Zeng SX; Dai MS; Keller DM; Lu H
    EMBO J; 2002 Oct; 21(20):5487-97. PubMed ID: 12374749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
    Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
    Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.
    Westfall MD; Mays DJ; Sniezek JC; Pietenpol JA
    Mol Cell Biol; 2003 Apr; 23(7):2264-76. PubMed ID: 12640112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
    Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
    Boominathan L
    Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NBP is the p53 homolog p63.
    Zeng X; Zhu Y; Lu H
    Carcinogenesis; 2001 Feb; 22(2):215-9. PubMed ID: 11181441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.
    Ellisen LW; Ramsayer KD; Johannessen CM; Yang A; Beppu H; Minda K; Oliner JD; McKeon F; Haber DA
    Mol Cell; 2002 Nov; 10(5):995-1005. PubMed ID: 12453409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains.
    Ghioni P; Bolognese F; Duijf PH; Van Bokhoven H; Mantovani R; Guerrini L
    Mol Cell Biol; 2002 Dec; 22(24):8659-68. PubMed ID: 12446784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and tissue distribution of novel KET/p63 splice variants.
    Bamberger C; Schmale H
    FEBS Lett; 2001 Jul; 501(2-3):121-6. PubMed ID: 11470269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p63 and p73: old members of a new family.
    Marin MC; Kaelin WG
    Biochim Biophys Acta; 2000 May; 1470(3):M93-M100. PubMed ID: 10799748
    [No Abstract]   [Full Text] [Related]  

  • 55. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
    Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
    Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential regulation of p63 and p73 expression.
    Waltermann A; Kartasheva NN; Dobbelstein M
    Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The emerging p53 gene family.
    Kaelin WG
    J Natl Cancer Inst; 1999 Apr; 91(7):594-8. PubMed ID: 10203277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
    Muttray AF; Cox RL; Reinisch CL; Baldwin SA
    Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P63 and P73: P53 mimics, menaces and more.
    Yang A; McKeon F
    Nat Rev Mol Cell Biol; 2000 Dec; 1(3):199-207. PubMed ID: 11252895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53.
    Ortt K; Sinha S
    FEBS Lett; 2006 Aug; 580(18):4544-50. PubMed ID: 16870177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.